1. Search Result
Search Result
Results for "

complement factor

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

4

Inhibitory Antibodies

27

Recombinant Proteins

5

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138281

    Complement System Inflammation/Immunology
    Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .
    Complement factor D-IN-2
  • HY-102034

    Complement System Inflammation/Immunology
    Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.
    Complement factor D-IN-1
  • HY-P99298

    RG 7417; TNX 234; Anti-CFD Recombinant Antibody

    Complement System Inflammation/Immunology
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
    Lampalizumab
  • HY-128570

    Complement System Inflammation/Immunology
    FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
    FD-IN-1
  • HY-147297

    BCX9930

    Complement System Inflammation/Immunology
    Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .
    Pelecopan
  • HY-148370A

    RG6299 sodium

    Complement System Others
    IONIS-FB-LRx sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .
    IONIS-FB-LRx sodium
  • HY-P2969

    Endogenous Metabolite Metabolic Disease
    Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46) .
    Complement factor I
  • HY-P2830

    Others Others
    Complement factor D is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Complement factor D
  • HY-W049802

    Complement System Inflammation/Immunology
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease .
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine
  • HY-148370

    RG6299

    Complement System Others
    IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .
    IONIS-FB-LRx
  • HY-127105
    Iptacopan
    Maximum Cited Publications
    6 Publications Verification

    LNP023

    Complement System Metabolic Disease Inflammation/Immunology
    Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 value of 10 nM. Iptacopan shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. Iptacopan targets the underlying cause of complement 3 glomerulopathy (C3G) .
    Iptacopan
  • HY-147605

    Complement System Inflammation/Immunology
    Factor B-IN-3 (Example 3 target compound) is a potent complement factor B inhibitor. Factor B-IN-3 can be used for the research of diseases related to inflammation and immunity .
    Factor B-IN-3
  • HY-147080

    ARC1905

    Complement System Others
    Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. Avacincaptad pegol sodium treats Geographic atrophy (GA) mice .
    Avacincaptad pegol sodium
  • HY-147606

    Complement System Inflammation/Immunology
    Factor B-IN-4 (Example 13 target compound) is a potent complement factor B inhibitor, with an IC50 of 1 μM. Factor B-IN-4 can be used for the research of diseases related to inflammation and immunity .
    Factor B-IN-4
  • HY-147604

    Complement System Inflammation/Immunology
    Factor B-IN-2 (Example 1 target compound) is a potent complement factor B inhibitor, with an IC50 of 1.5 μM. Factor B-IN-2 can be used for the research of diseases related to inflammation and immunity .
    Factor B-IN-2
  • HY-147607

    Complement System Inflammation/Immunology
    Factor B-IN-5 (Example 5 target compound) is a potent complement factor B inhibitor, with an IC50 of 1.2 μM. Factor B-IN-5 can be used for the research of diseases related to inflammation and immunity .
    Factor B-IN-5
  • HY-117930
    Danicopan
    3 Publications Verification

    ACH-4471

    Complement System Inflammation/Immunology
    Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
    Danicopan
  • HY-139588

    ALXN2050; ACH 0145228; ACH-5228

    Complement System Metabolic Disease Inflammation/Immunology
    Vemircopan (ALXN2050) is an orally active complement factor D inhibitor. Vemircopan is promising for research of paroxysmal nocturnal hemoglobinuria .
    Vemircopan
  • HY-122700

    Complement System Inflammation/Immunology
    Factor D inhibitor 6 is a potent, highly selective and orally active factor D (FD) inhibitor with an IC50 of 30 nM and a Kd of 6 nM. Factor D inhibitor 6 is inactive against factor B, lassical and lectin complement-pathway activation, and a broad assay panel of receptors, ion channels, kinases and proteases .
    Factor D inhibitor 6
  • HY-P3204
    POT-4
    1 Publications Verification

    AL-78898A

    Complement System Metabolic Disease
    POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
    POT-4
  • HY-P3204A

    AL-78898A TFA

    Complement System Metabolic Disease
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .
    POT-4 TFA
  • HY-163684

    Complement System Inflammation/Immunology
    Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB) .
    Zoracopan
  • HY-P2751

    Others Others
    Elastase, Human leukocytes is a serine protease present in the nitrogen-loving granules of neutrophils. Elastase, Human leukocytes potential substrates include almost all components of the extracellular matrix, as well as a variety of proteins such as coagulation factors, complement, immunoglobulins and cytokines. It has a strong proteolytic function and participates in the pathogenesis of inflammatory tissue damage .
    Elastase, Human leukocytes
  • HY-127105A
    Iptacopan hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    LNP023 hydrochloride

    Complement System Metabolic Disease Inflammation/Immunology
    LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 inhibits factor B with an IC50 value of 10 nM .
    Iptacopan hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: